US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

46.03

-1.2800-2.71%

Volume:69.89K

Turnover:3.30M

Market Cap:3.62B

PE:-23.25

High:48.47

Open:47.75

Low:45.95

Close:47.31

52wk High:49.31

52wk Low:10.91

Shares:78.54M

Float Shares:72.55M

Volume Ratio:0.48

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9800

EPS(LYR):-1.9755

ROE:-25.17%

ROA:-19.80%

PB:6.46

PE(LYR):-23.30

Loading ...

Overview Company News Filings

Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2

Spyre Therapeutics Grants Stock Options to Six New Employees

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares

Spyre Therapeutics (SYRE) Valuation Check After Recent Drop And Focus On 2026 Trial Readouts

Simply Wall St.

Did Bullish Analyst Initiations on Spyre’s Autoimmune Pipeline Just Shift Spyre Therapeutics’ (SYRE) Investment Narrative?

Simply Wall St.

Spyre Therapeutics (SYRE) Valuation Check After Encouraging Phase 1 Data and Better-Than-Expected Earnings

Simply Wall St.

Spyre Therapeutics Announces Grants of Inducement Awards

Does Spyre Therapeutics' (SYRE) Analyst Upgrade Reveal Growing Conviction in Its Autoimmune Pipeline Strategy?

Simply Wall St.

Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares

Spyre Therapeutics Inc : Jonestrading Raises to Buy From Hold

THOMSON REUTERS

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics : Deutsche Bank Cuts Target Price to $42 From $43

THOMSON REUTERS

Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares

Spyre Therapeutics reports third quarter net loss of $11.2 million

Spyre Therapeutics Reports Positive Phase 1 Results for Long-Acting Anti-IL-23 Antibody SPY003

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Spy003, Its Novel, Half-Life Extended Anti-Il-23 Antibody

THOMSON REUTERS

Spyre Therapeutics: Spy003 Well Tolerated at All Dose Levels, Favorable Safety Profile Consistent With Anti-Il-23 Class

THOMSON REUTERS

Spyre Therapeutics Inc - Skyline and Skyway Trials to Provide 6 Readouts in 2026

THOMSON REUTERS

Spyre Therapeutics - Spy003 Shows About 85-Day Half-Life Supporting Quarterly or Twice Annual Maintenance Dosing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/SYRE/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":46.03,"timestamp":1774881298398,"preClose":47.31,"halted":0,"volume":69886,"delay":0,"changeRate":-0.027055590784189412,"floatShares":72553500,"shares":78540200,"eps":-1.98,"marketStatus":"Trading","change":-1.28,"latestTime":"03-30 10:35:02 EDT","open":47.75,"high":48.47,"low":45.95,"amount":3297293.46258,"amplitude":0.053266,"askPrice":46.24,"askSize":12,"bidPrice":45.87,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.98,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774900800000},"marketStatusCode":2,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":47.31,"preHourTrading":{"tag":"盘前","latestPrice":48.02,"preClose":47.31,"latestTime":"09:29 EDT","volume":1510,"amount":72558.4445,"timestamp":1774877369081,"change":0.71,"changeRate":0.015007,"amplitude":0.039949},"postHourTrading":{"tag":"盘后","latestPrice":47.31,"preClose":47.31,"latestTime":"17:40 EDT","volume":17333,"amount":820017.23,"timestamp":1774647614677,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.476091,"impliedVol":1.1181,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":72553500,"roa":"-19.80%","roe":"-25.17%","lyrEps":-1.975476,"volumeRatio":0.476091,"shares":78540200,"dividePrice":0,"high":48.47,"amplitude":0.053266,"preClose":47.31,"low":45.95,"week52Low":10.91,"pbRate":"6.46","week52High":49.305,"institutionHeld":0,"latestPrice":46.03,"committee":-0.846154,"eps":-1.98,"divideRate":0,"volume":69886,"delay":0,"ttmEps":-1.98,"open":47.75,"prevYearClose":32.76,"prevWeekClose":47.31,"prevMonthClose":43.01,"prevQuarterClose":32.76,"fiveDayClose":42.76,"twentyDayClose":42.49,"sixtyDayClose":32.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"SYRE","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-04","symbol":"SYRE","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762232400000,"reportTimeType":"post","actualEps":-0.15},{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":15,"updateTime":1766030400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2026-03-27","current":-23.247475,"percent":0,"low":-24.0474,"twenty":-8.969358,"median":-4.994463,"eighty":-3.931452,"high":-0.199399,"avg":-7.211774,"sd":5.100799,"marketCap":3732228593},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-31","current":-9.090497,"twenty":-6.704732,"median":-4.696933,"eighty":-3.700564,"marketCap":1880042140},{"date":"2025-11-07","current":-11.662076,"twenty":-6.790267,"median":-4.714264,"eighty":-3.706047,"marketCap":1737287790},{"date":"2025-11-14","current":-11.787083,"twenty":-6.900444,"median":-4.731283,"eighty":-3.707046,"marketCap":1755909901},{"date":"2025-11-21","current":-12.224606,"twenty":-6.988263,"median":-4.745208,"eighty":-3.707046,"marketCap":1821087291},{"date":"2025-11-28","current":-15.625828,"twenty":-7.239349,"median":-4.751954,"eighty":-3.713244,"marketCap":2327763900},{"date":"2025-12-05","current":-17.454049,"twenty":-7.296115,"median":-4.772037,"eighty":-3.728167,"marketCap":2600112276},{"date":"2025-12-12","current":-17.896781,"twenty":-7.380142,"median":-4.779357,"eighty":-3.742192,"marketCap":2666065586},{"date":"2025-12-19","current":-17.433215,"twenty":-7.489402,"median":-4.800924,"eighty":-3.751648,"marketCap":2597008591},{"date":"2025-12-26","current":-17.214453,"twenty":-7.525937,"median":-4.815979,"eighty":-3.763383,"marketCap":2564419896},{"date":"2026-01-02","current":-17.063404,"twenty":-7.573901,"median":-4.841253,"eighty":-3.771122,"marketCap":2541918178},{"date":"2026-01-09","current":-15.698748,"twenty":-7.596248,"median":-4.85056,"eighty":-3.792677,"marketCap":2338626798},{"date":"2026-01-16","current":-17.235288,"twenty":-7.641035,"median":-4.868549,"eighty":-3.827277,"marketCap":2567523581},{"date":"2026-01-23","current":-17.756149,"twenty":-7.65516,"median":-4.878917,"eighty":-3.836222,"marketCap":2645115711},{"date":"2026-01-30","current":-17.49051,"twenty":-7.716495,"median":-4.891913,"eighty":-3.850233,"marketCap":2605543725},{"date":"2026-02-06","current":-17.157159,"twenty":-7.797537,"median":-4.900675,"eighty":-3.876725,"marketCap":2555884762},{"date":"2026-02-13","current":-18.146794,"twenty":-7.885881,"median":-4.903471,"eighty":-3.891573,"marketCap":2703309809},{"date":"2026-02-20","current":-23.527864,"twenty":-7.934432,"median":-4.916265,"eighty":-3.909092,"marketCap":3504922382},{"date":"2026-02-27","current":-21.83597,"twenty":-8.038472,"median":-4.931737,"eighty":-3.918816,"marketCap":3389008076},{"date":"2026-03-06","current":-20.540487,"twenty":-8.323214,"median":-4.953617,"eighty":-3.922049,"marketCap":3187945256},{"date":"2026-03-13","current":-20.449399,"twenty":-8.618907,"median":-4.962688,"eighty":-3.925813,"marketCap":3173808027},{"date":"2026-03-20","current":-21.41089,"twenty":-8.906386,"median":-4.973688,"eighty":-3.927002,"marketCap":3323034338},{"date":"2026-03-27","current":-24.0474,"twenty":-8.969358,"median":-4.994463,"eighty":-3.931452,"marketCap":3732228593}],"updateTime":1774881302877},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602510876","title":"Press Release: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510876","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510876?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:00","pubTimestamp":1768222800,"startTime":"0","endTime":"0","summary":"\"6 in '26\" expected proof-of-concept  readouts across SKYLINE and SKYWAY trials. SKYLINE platform trial in ulcerative colitis  recruiting faster than expected with SPY001 enrollment complete ahead of schedule; Part A readouts accelerated, now expected to start in Q2. SKYWAY basket trial enrollment on track across rheumatoid arthritis , psoriatic arthritis , and axial spondyloarthritis ; All readouts expected in 4Q 2026. WALTHAM, Mass., Jan. 12, 2026  -- Spyre Therapeutics, Inc. , a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease  and rheumatic diseases, today highlighted its 2026 priorities including six expected POC readouts . The Company also expanded its leadership team with the appointment of Kate Tansey Chevlen as CCO. Ms. Tansey Chevlen is a seasoned biopharma commercial leader with nearly two decades of experience driving strategy, execution, and growth across U.S. an","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CCO","LU2506951792.HKD","LU0823414478.USD","SYRE","LU2357125470.USD","BK4539","BK4007","LU2294711713.HKD","LU0823414551.USD","RA","BK4139","LU2249611893.SGD","BK4009"],"gpt_icon":0},{"id":"2602662318","title":"Spyre Therapeutics Grants Stock Options to Six New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2602662318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602662318?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:06","pubTimestamp":1767906418,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. has granted stock options to six non-executive employees as equity inducement awards under its 2018 Equity Inducement Plan. The awards cover a total of 42,000 shares of common stock with an exercise price of $30.58 per share, reflecting the closing price on January 2, 2026. Each option has a ten-year term and vests over four years, with one-fourth of the shares vesting on the first anniversary of the employee's start date and the remainder vesting in equal monthly installments thereafter.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contai","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4QV6f1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","LU0314104364.USD","SG9999014039.USD","SG9999014005.SGD","BK4139","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","SYRE","NDAQ","BK4585","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2602313990","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2602313990","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602313990?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:05","pubTimestamp":1767906300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  08, 2026  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/08/3215780/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4539","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2601828317","title":"Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2601828317","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601828317?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:37","pubTimestamp":1767753430,"startTime":"0","endTime":"0","summary":"Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL2wl25h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2601600588","title":"Spyre Therapeutics (SYRE) Valuation Check After Recent Drop And Focus On 2026 Trial Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2601600588","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601600588?lang=en_us&edition=fundamental","pubTime":"2026-01-06 13:21","pubTimestamp":1767676873,"startTime":"0","endTime":"0","summary":"Event driven move in Spyre Therapeutics\nSpyre Therapeutics (SYRE) shares fell about 7% on 2 January 2026, as traders reacted to biotech sector volatility and refocused on the company’s key 2026 clinical readouts for SKYLINE-UC and SKYWAY-RD.\nSee our latest analysis for Spyre Therapeutics.\nThat 7% single day fall sits within a choppy but strong backdrop, with a 90 day share price return of 69.46% and a 1 year total shareholder return of 23.04%. This suggests momentum has cooled recently after...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-recent-drop-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-recent-drop-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2592194812","title":"Did Bullish Analyst Initiations on Spyre’s Autoimmune Pipeline Just Shift Spyre Therapeutics’ (SYRE) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194812","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194812?lang=en_us&edition=fundamental","pubTime":"2025-12-20 01:13","pubTimestamp":1766164430,"startTime":"0","endTime":"0","summary":"In recent coverage, Mizuho and Citi both initiated positive ratings on Spyre Therapeutics, highlighting its half-life extended monoclonal antibody pipeline for inflammatory bowel and other autoimmune diseases.\nAnalysts emphasized Spyre’s ability to explore novel antibody combinations and its rheumatic disease program, with several firms now expressing broad confidence in the company’s development approach.\nWe’ll now explore how this wave of optimistic analyst coverage, particularly around...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/did-bullish-analyst-initiations-on-spyres-autoimmune-pipelin","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/did-bullish-analyst-initiations-on-spyres-autoimmune-pipelin","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4112","SYRE"],"gpt_icon":0},{"id":"2589684262","title":"Spyre Therapeutics (SYRE) Valuation Check After Encouraging Phase 1 Data and Better-Than-Expected Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2589684262","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589684262?lang=en_us&edition=fundamental","pubTime":"2025-12-06 13:19","pubTimestamp":1764998361,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) drew fresh attention after reporting Phase 1 data that pointed to encouraging safety and activity signals for its investigational IBD antibodies, along with earnings per share that topped expectations.\nSee our latest analysis for Spyre Therapeutics.\nThose upbeat trial results and recent conference visibility seem to be feeding into strong momentum, with the share price up sharply on a 30 day and 90 day basis and a hefty three year total shareholder return, though...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-encouraging-ph","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-check-after-encouraging-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2589810630","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2589810630","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589810630?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:05","pubTimestamp":1764968700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec.  05, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/05/3200978/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","SYRE","LENZ","BK4007"],"gpt_icon":0},{"id":"2589576859","title":"Does Spyre Therapeutics' (SYRE) Analyst Upgrade Reveal Growing Conviction in Its Autoimmune Pipeline Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589576859","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589576859?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:33","pubTimestamp":1764894829,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics recently presented at Evercore’s 8th Annual Healthcare Conference in Coral Gables, Florida, while also attracting fresh attention from Wall Street research.\nA key development was an analyst at JonesTrading assigning a buy rating to Spyre Therapeutics, highlighting increased confidence backed by the analyst’s strong recent track record.\nWith that backdrop, we’ll explore how the JonesTrading upgrade shapes Spyre Therapeutics’ investment narrative and what it may mean for...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/does-spyre-therapeutics-syre-analyst-upgrade-reveal-growing","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/does-spyre-therapeutics-syre-analyst-upgrade-reveal-growing","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SYRE"],"gpt_icon":0},{"id":"2588531074","title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588531074","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588531074?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:52","pubTimestamp":1764816779,"startTime":"0","endTime":"0","summary":"Cameron Turtle, Chief Executive Officer of Spyre Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL2XX6vs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2588678748","title":"Spyre Therapeutics Inc : Jonestrading Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2588678748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588678748?lang=en_us&edition=fundamental","pubTime":"2025-12-01 11:48","pubTimestamp":1764560928,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X702S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2581831157","title":"Spyre Therapeutics Announces Grants of Inducement Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831157","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831157?lang=en_us&edition=fundamental","pubTime":"2025-11-08 05:05","pubTimestamp":1762549500,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Nov.  07, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and ant","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/07/3183951/0/en/Spyre-Therapeutics-Announces-Grants-of-Inducement-Awards.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","SYRE","LENZ"],"gpt_icon":0},{"id":"2581062047","title":"Spyre Therapeutics  : Deutsche Bank Cuts Target Price to $42 From $43","url":"https://stock-news.laohu8.com/highlight/detail?id=2581062047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581062047?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:12","pubTimestamp":1762431143,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nAQN2L6FUK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2581080024","title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581080024","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581080024?lang=en_us&edition=fundamental","pubTime":"2025-11-06 10:15","pubTimestamp":1762395352,"startTime":"0","endTime":"0","summary":"Cameron Turtle, Chief Executive Officer and Director of Spyre Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL9CyfZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Spyre Therapeutics CEO Cameron Turtle Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2581314767","title":"Spyre Therapeutics reports third quarter net loss of $11.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581314767","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581314767?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:38","pubTimestamp":1762292287,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. reported a net loss of $11.2 million for the third quarter of 2025, an improvement compared to a net loss of $69.0 million in the same period in 2024. Total operating expenses for the quarter were $56.9 million, slightly up from $55.4 million in the prior year. Research and development expenses reached $45.2 million, while general and administrative expenses totaled $11.6 million. The company recorded a gain on sale of in-process research and development asset of $10.0 million for the nine-month period. Interest income for the quarter was $5.4 million, and total other income  was $45.7 million. As of September 30, 2025, Spyre reported $783 million in pro forma cash, cash equivalents, and marketable securities, projecting a cash runway into the second half of 2028. During the period, Spyre announced positive interim Phase 1 results for its SPY003 antibody and initiated a Phase 2 basket study of SPY072 in rheumatic diseases. The company is on track for six proof-o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL7b8zF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2581769339","title":"Spyre Therapeutics Reports Positive Phase 1 Results for Long-Acting Anti-IL-23 Antibody SPY003","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769339","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769339?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290107,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. announced positive interim Phase 1 results from its first-in-human trial of SPY003, an investigational, extended half-life antibody targeting the p19 subunit of IL-23. The study was a randomized, double-blind, placebo-controlled trial involving 59 healthy adult participants across multiple dosing cohorts. According to interim findings as of September 19, 2025, SPY003 was well tolerated at all dose levels, with no serious adverse events observed and a favorable safety profile consistent with the anti-IL-23 class. The most common treatment-emergent adverse event was headache. SPY003 exhibited an approximate half-life of 85 days, supporting the potential for quarterly or twice-annual maintenance dosing. The company stated that SPY003 is expected to advance to the ongoing Part A of the SKYLINE Phase 2 platform trial. The interim results have been announced and are not pending future presentation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL9bzvxq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","BK4585","LU0314104364.USD","BK4139","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BKPKM429.USD","BK4112","SYRE"],"gpt_icon":0},{"id":"2581766026","title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for Spy003, Its Novel, Half-Life Extended Anti-Il-23 Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2581766026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581766026?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8HNW43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2581762095","title":"Spyre Therapeutics: Spy003 Well Tolerated at All Dose Levels, Favorable Safety Profile Consistent With Anti-Il-23 Class","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762095","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762095?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8HNW43:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2581762064","title":"Spyre Therapeutics Inc - Skyline and Skyway Trials to Provide 6 Readouts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2581762064","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581762064?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290061,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8HNW43:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2581620997","title":"Spyre Therapeutics - Spy003 Shows About 85-Day Half-Life Supporting Quarterly or Twice Annual Maintenance Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581620997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581620997?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290061,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nTUA8HNW43:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":85,"code":"91000000","status":"200"}]}}